Table 3 Summary of adverse events
Adverse event | Niraparib monotherapy (n = 18) | Niraparib combined therapy (n = 4) | ||
|---|---|---|---|---|
Any grade | Grade 3 or 4 | Any grade | Grade 3 or 4 | |
Number of patients (percent) | ||||
Nausea | 10 (55.6) | 0 (0) | 2 (50.0) | 0 (0) |
Thrombocytopenia | 8 (44.4) | 3 (16.7) | 3 (75.0) | 1 (25.0) |
Anemia | 6 (33.3) | 1 (5.6) | 3 (75.0) | 1 (25.0) |
Decreased appetite | 6 (33.3) | 0 (0) | 1 (25.0) | 0 (0) |
Fatigue or asthenia | 5 (27.8) | 0 (0) | 3 (75.0) | 0 (0) |
Constipation | 5 (27.8) | 0 (0) | 1 (25.0) | 0 (0) |
Insomnia | 5 (27.8) | 0 (0) | 0 (0) | 0 (0) |
Neutropenia | 3 (16.7) | 1 (5.6) | 2 (50.0) | 1 (25.0) |
Vomiting | 3 (16.7) | 1 (5.6) | 0 (0) | 0 (0) |
Dyspepsia | 3 (16.7) | 1 (5.6) | 0 (0) | 0 (0) |
Headache | 2 (11.1) | 0 (0) | 1 (25.0) | 0 (0) |
Abdominal distention | 2 (11.1) | 0 (0) | 0 (0) | 0 (0) |
Dizziness | 1 (5.6) | 0 (0) | 1 (25.0) | 0 (0) |
Dysgeusia | 1 (5.6) | 0 (0) | 0 (0) | 0 (0) |
Back pain | 1 (5.6) | 0 (0) | 0 (0) | 0 (0) |
Diarrhea | 1 (5.6) | 0 (0) | 0 (0) | 0 (0) |
Maculopapular rash | 1 (5.6) | 0 (0) | 0 (0) | 0 (0) |
Stomatitis | 1 (5.6) | 0 (0) | 0 (0) | 0 (0) |
Dry mouth | 1 (5.6) | 0 (0) | 0 (0) | 0 (0) |
Abdominal pain | 0 (0) | 0 (0) | 1 (25.0) | 0 (0) |
Newly observed | ||||
Leg swelling | 1 (5.6) | 0 (0) | 0 (0) | 0 (0) |
Led to discontinuation of intervention | 1 (5.6) | – | 0 (0) | – |
Led to dose reduction | 3 (16.7) | – | 1 (25.0) | – |
Led to dose interruption | 2 (11.1) | – | 2 (50.0) | – |